Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

PubWeight™: 4.35‹?› | Rank: Top 1%

🔗 View Article (PMC 2587454)

Published in Cancer Res on August 15, 2008

Authors

Derek Y Chiang1, Augusto Villanueva, Yujin Hoshida, Judit Peix, Philippa Newell, Beatriz Minguez, Amanda C LeBlanc, Diana J Donovan, Swan N Thung, Manel Solé, Victoria Tovar, Clara Alsinet, Alex H Ramos, Jordi Barretina, Sasan Roayaie, Myron Schwartz, Samuel Waxman, Jordi Bruix, Vincenzo Mazzaferro, Azra H Ligon, Vesna Najfeld, Scott L Friedman, William R Sellers, Matthew Meyerson, Josep M Llovet

Author Affiliations

1: Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Articles citing this

(truncated to the top 100)

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60

Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42

Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology (2011) 2.33

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10

DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells. PLoS One (2015) 2.02

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68

Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68

Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology (2014) 1.59

Lung adenocarcinoma subtypes based on expression of human airway basal cell genes. Eur Respir J (2013) 1.59

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell (2014) 1.50

New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46

Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (2013) 1.41

Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin (2010) 1.40

Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics (2011) 1.39

Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology (2014) 1.35

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26

Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology (2013) 1.26

Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest (2012) 1.24

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A (2015) 1.18

Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15

Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14

Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14

Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One (2012) 1.11

Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology (2012) 1.10

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Rep (2015) 1.08

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol (2010) 1.08

Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Brief Bioinform (2011) 1.08

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res (2012) 1.05

Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05

Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05

SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer (2014) 1.03

Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis (2010) 1.01

Polymeric Nanostructures for Imaging and Therapy. Chem Rev (2015) 0.99

Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med (2009) 0.97

Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med (2008) 0.93

Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med (2014) 0.92

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial biogenesis and respiration via estrogen-related receptor α (ERRα). J Biol Chem (2013) 0.92

Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer (2014) 0.92

Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol (2013) 0.91

Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int (2013) 0.91

Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One (2012) 0.91

Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. Cancer Cell (2014) 0.90

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br J Cancer (2014) 0.90

Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89

Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget (2016) 0.88

Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J (2009) 0.88

Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88

Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer (2010) 0.87

MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway. Oncogene (2015) 0.87

USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds. Proc Natl Acad Sci U S A (2016) 0.85

p16 Stimulates CDC42-dependent migration of hepatocellular carcinoma cells. PLoS One (2013) 0.85

Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish. PLoS Genet (2015) 0.84

Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84

Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83

Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC Cancer (2010) 0.83

Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int (2015) 0.83

Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. PLoS One (2010) 0.83

A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One (2013) 0.82

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res (2014) 0.81

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut (2016) 0.81

Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver. Cell Mol Gastroenterol Hepatol (2015) 0.80

Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol (2016) 0.80

Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology (2014) 0.80

IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis (2015) 0.79

Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas. BMC Med Genomics (2015) 0.79

Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. Semin Cell Dev Biol (2014) 0.79

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid (2014) 0.78

Articles cited by this

Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74

Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32

GenePattern 2.0. Nat Genet (2006) 29.07

Hepatocellular carcinoma. Lancet (2003) 22.54

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72

Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05

Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67

AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol (2006) 7.52

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res (2006) 5.97

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17

Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97

Common markers of proliferation. Nat Rev Cancer (2006) 3.85

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics (2005) 3.66

Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53

Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene (2002) 2.23

A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology (2006) 1.99

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut (2007) 1.98

Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology (2000) 1.77

Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology (1996) 1.65

Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64

Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res (1994) 1.63

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62

Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol (2001) 1.62

Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis (2005) 1.59

Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res (2007) 1.56

Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50

Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene (2006) 1.43

Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology (2004) 1.35

Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene (2006) 1.24

PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology (2003) 1.23

Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology (2007) 1.04

Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett (2006) 1.04

Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene (2005) 1.03

Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo. World J Gastroenterol (2006) 0.83

Articles by these authors

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35

Hepatocellular carcinoma. Lancet (2003) 22.54

Signatures of mutational processes in human cancer. Nature (2013) 21.63

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

Hepatocellular carcinoma. Lancet (2012) 18.09

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

A landscape of driver mutations in melanoma. Cell (2012) 12.61

High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03

LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61

Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89